Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EmpaCHD: Empagliflozin in Adult Patients With Congenital Heart Disease
NCT06260059Phase 4Active, not recruiting
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in congenital heart disease (CHD) and heart failure (HF) comparing Empagliflozin 10 MG with Placebo (2 arms). Primary endpoints: Ejection Fraction at 1 year, Myocardial characteristics (T1 mapping of cMRI) at 1 year and 5 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
congenital heart disease (CHD)heart failure (HF)
Beyond the preview
Go deeper on NCT06260059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06260059.